The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
 
Daniel P. Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma; Abbvie; Abbvie; Abbvie; Abbvie; AIkido Pharma; AIkido Pharma; AIkido Pharma; AIkido Pharma; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Dendreon; Dendreon; Dendreon; Dendreon; Endocyte; Endocyte; Endocyte; Endocyte; Genentech; Genentech; Genentech; Genentech; Genomic Health; Genomic Health; Genomic Health; Genomic Health; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Medivation; Medivation; Medivation; Medivation; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; POINT Biopharma; POINT Biopharma; POINT Biopharma; POINT Biopharma; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Tolmar; Tolmar; Tolmar; Tolmar
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Sanofi; Sanofi; Sanofi; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics
 
Rohit K. Jain
Honoraria - Curio Science; Curio Science; Curio Science; Curio Science; DAVA Oncology; DAVA Oncology; DAVA Oncology; DAVA Oncology; NCCN/Pfizer; NCCN/Pfizer; NCCN/Pfizer; NCCN/Pfizer; OncLive/MJH Life Sciences; OncLive/MJH Life Sciences; OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Consulting or Advisory Role - AVEO; AVEO; AVEO; AVEO; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pfizer; Pfizer; Pfizer; Pfizer; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Seagen; Seagen; Seagen; Seagen; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Bristol Myers Squibb; Bristol Myers Squibb; Bristol Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; NCI; NCI; NCI; NCI
 
Manojkumar Bupathi
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer
 
Arjun V. Balar
Leadership - GT Biopharma; GT Biopharma; GT Biopharma; GT Biopharma
Stock and Other Ownership Interests - GT Biopharma; GT Biopharma; GT Biopharma; GT Biopharma
Honoraria - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck; Merck; Merck; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Cerulean Pharma; Cerulean Pharma; Cerulean Pharma; Cerulean Pharma; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Incyte; Incyte; Incyte; Incyte; Merck; Merck; Merck; Merck; Nektar; Nektar; Nektar; Nektar; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Seagen; Seagen; Seagen; Seagen
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical; ECOM Medical; ECOM Medical; ECOM Medical
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Astellas Medivation; Astellas Medivation; Astellas Medivation; Astellas Medivation; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BeyondSpring Pharmaceuticals (Inst); BeyondSpring Pharmaceuticals (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Epizyme (Inst); Epizyme (Inst); Epizyme (Inst); Epizyme (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); MacroGenics (Inst); MacroGenics (Inst); MacroGenics (Inst); MacroGenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; Astellas Medivation; Astellas Medivation; Astellas Medivation; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech; Janssen; Janssen; Janssen; Janssen; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Prometheus; Prometheus; Prometheus; Prometheus
 
Saby George
Consulting or Advisory Role - AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Corvus Pharmaceuticals; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Aravive (Inst); Aravive (Inst); Aravive (Inst); Aravive (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst); Surface Oncology (Inst); Surface Oncology (Inst); Surface Oncology (Inst)
 
Phillip Lee Palmbos
Research Funding - Immunomedics; Immunomedics; Immunomedics; Immunomedics; Roche; Roche; Roche; Roche
 
Luke T. Nordquist
No Relationships to Disclose
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech; Janssen Biotech; Janssen Biotech; Janssen Biotech
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Chethan Ramamurthy
Consulting or Advisory Role - Seagen; Seagen; Seagen; Seagen
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genzyme; Genzyme; Genzyme; Genzyme; Immunomedics; Immunomedics; Immunomedics; Immunomedics; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; Incyte; Incyte; Incyte; Incyte; Medscape; Medscape; Medscape; Medscape; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; UroToday; UroToday; UroToday; UroToday
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; MEI Pharma; MEI Pharma; MEI Pharma; MEI Pharma; Merck; Merck; Merck; Merck; Nektar; Nektar; Nektar; Nektar; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Seagen; Seagen; Seagen; Seagen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Chandler H. Park
No Relationships to Disclose
 
Julia Tonelli
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences
 
Morganna Vance
Employment - Artiva; Artiva; Artiva; Artiva; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Stock and Other Ownership Interests - Artiva; Artiva; Artiva; Artiva; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Huafeng Zhou
Employment - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BostonGene; BostonGene; BostonGene; BostonGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dyania Health; Dyania Health; Dyania Health; Dyania Health; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Fresenius Kabi; Fresenius Kabi; Fresenius Kabi; Fresenius Kabi; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Janssen; Janssen; Janssen; Lucence; Lucence; Lucence; Lucence; Merck; Merck; Merck; Merck; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; PureTech; PureTech; PureTech; PureTech; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Silverback Therapeutics; Silverback Therapeutics; Silverback Therapeutics; Silverback Therapeutics; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst)